Drug Trial Radar · NCT00125554
Metyrapone as Additive Treatment in Major Depression
Last checked: Nov 20, 2026Latest source record: Aug 12, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
May 1998
Primary completion
Not stated
Study completion Jul 2001
Sponsor
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.
Conditions
- Major Depressive Disorder
Interventions
MetyraponeDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Two psychometric criteria defined by the number of responders and time to onset-of-action. The number of responders was considered twice after 3 and 5 weeks by defining the treatment response as a 30% and 50% reduction
- the course of concentrations of ACTH, cortisol, 11-deoxycortisol and DHEA.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dept. of Psychiatry and Psychotherapy, UKE
Hamburg, Free and Hanseatic City of Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.